NEBRASKA

Good Life. Great Mission.

DEPT. OF HEALTH AND HUMAN SERVICES

Jim Pillen, Governor

REQUEST FOR APPLICATIONS – STATE FUNDS

The State of Nebraska, Department of Health and Human Services, Division of Public Health ("DHHS") Health Services & Systems Unit, is issuing this Request for Applications ("RFA") for the purposes of entering into grant agreement(s) ("grant" or "grants") and awarding state funds to an eligible and qualified entity or entities to provide non-embryonic stem cell research. A more detailed description may be found in **Project Description, Section 2.**

RFA #	RELEASE DATE
R-6251	March 9, 2026
APPLICATION DUE DATE	**POINT OF CONTACT**
April 26, 2026	Office of Procurement and Grants

INITIAL PERIOD OF PERFORMANCE	TOTAL FUNDING AVAILABLE
July 1, 2026 - June 30, 2027	$436,500.00
FUNDING CAP (MAX AWARD PER APPLICANT)	
$110,000.00	

Grantees receiving grants may only be paid up to the actual and allowable costs (as defined herein) of completing the **Project Description, Section 2**. No Grants resulting from this RFA will be fee-for-service contracts, regardless of the method of payment, and no Grantee may keep a profit from its grant. More details about the terms of this funding is set forth in **Terms**, **Section 5**, below.

A copy of this RFA may be found online at DHHS' website at http://dhhs.ne.gov/Pages/Grants-and-Contract-Opportunities.aspx. Until final Grants are signed, all other information pertinent to this RFA, including but not limited to any amendments or addenda, will be posted on the DHHS website.

Table of Contents

1. RFA OVERVIEW

1.1. Funding Information

Funding Agency	Statutory Authorization
State of Nebraska General Funds	Neb Rev Stat 71-8801 through 71-8806

The total anticipated available funds for Grant(s) under this RFA is $436,500 (four hundred thirty-six thousand five hundred dollars). A total award of this amount of funds is not guaranteed, but is subject to the Applications received, to actual money appropriated to DHHS and to DHHS' discretion. DHHS may establish a cap on total amount of funds that any one Applicant, or Applicants acting jointly, may request. Any cap shall be set forth in the **Award of Funding, Section 1.5**, below. The total funds may be split among multiple Grantees at the discretion of DHHS.

1.2. Budget Period

The Budget Period is the time during which a successful Applicant may incur costs to carry out the work authorized under this RFA and the resulting Grant. For the purposes of this RFA and resulting grant(s), DHHS will apply the definition of "budget period", as defined in **Glossary of Terms, Section 6**. The initial Budget Period for this RFA is from July 1, 2026, to June 30, 2027. This period may be extended by DHHS for up to one year.

For the initial Period of Performance, all costs must be liquidated (i.e., spent) by June 30, 2027, and invoiced to DHHS by August 30, 2027, unless a one-year extension is granted. These dates are dependent on DHHS' own ability to timely process payments. They may be subject to change; final dates will be included in the final Grant between the parties. If an Applicant believes it cannot meet these deadlines, it should not apply for funding under this RFA. **Obligation and liquidation deadlines may be extended, but no extensions are guaranteed**. Future Budget Periods, as allowed by DHHS, may have different obligation and liquidation deadlines.

1.3. Eligible Entities

Grants will be awarded to Nebraska institutions or researchers as defined below:

Sponsoring Institution: Preference will be given to funding proposals submitted by Nebraska institutions that have an ongoing, large-scale research program that is conducive to the completion of a complex project in stem cell research that does not use human embryonic stem cells.

Principal Investigator: The leader of a project is the "principal investigator". Researchers with a doctoral degree in science (PhD or equivalent), or a professional degree in a medical field (MD, DMD, DVM, or similar), are eligible to submit a proposal to the Stem Cell Research Advisory Committee as a Principal Investigator (PI). The PI must be employed at an institution in Nebraska that meets the criteria for "Sponsoring Institution" (see above). Researchers that are classified as post-doctorates or fellows are not eligible to apply.

1.4. Applicable Law

For purposes of this RFA and resulting Grant, DHHS will apply Uniform Grant Guidance, in addition to all applicable state law.

Additional state statutes and regulations may apply to the funding contained herein. These may be included in the Grant itself.

Further information about allowable costs and activities may be set forth herein.

1.5. Award of Funding

DHHS will evaluate Applications in the manner set forth herein. An Intent to Award will be posted on the DHHS Website with selected Applicants. Funds will be awarded through a written agreement, termed a Grant, which will incorporate this RFA by reference. No promise for funds is binding on DHHS, and no funds will be paid to any Applicant until a Grant has been executed by both the Applicant and DHHS.

The amount of money available for new grants is approximately $436,500.00 (four hundred thirty-six thousand, five hundred dollars). The maximum per grant award is capped at $110,000.00 (one hundred ten thousand dollars) for 12 (twelve) months.

Per Neb. Rev. Stat. § 71-8805, each Sponsoring Institution or researcher must use these grant funds to provide a dollar-for-dollar match of funds received from sources other than funds provided by the State of Nebraska for nonembryonic stem cell research.

2. PROJECT DESCRIPTION

The Nebraska Department of Health and Human Services, Division of Public Health (DHHS), is issuing this RFA for the purpose of funding non-embryonic stem cell research by Nebraska research institutions.

2.1. Background and Purpose

In the 2008 legislative session, the Stem Cell Research Act (Neb. Rev. Stat. §§ 71-8801 et seq., "The Act") was passed. The Act established the Stem Cell Research Advisory Committee ("The Committee"). The Committee is responsible for developing a grant process and making grants to Nebraska institutions or researchers to conduct stem cell research that does not use human embryonic stem cells. The Act defines the types of research projects that are acceptable. The Act states that:

> "No state facilities, no state funds, fees, or charges, and no investment income on state funds shall be used to destroy human embryos for the purpose of research. In no case shall state facilities, state funds, fees, or charges, or investment income on state funds be used to create a human embryo by somatic cell nuclear transfer for any purpose."

The stem cell grants are funded with state tobacco settlement dollars.

For purposes of the Act, human embryo means the developing human organism from the time of fertilization until the end of the eighth week of gestation and includes an embryo or developing human organism created by somatic cell nuclear transfer; and somatic cell nuclear transfer means a technique in which the nucleus of an oocyte is replaced with the nucleus of a somatic cell.

Members of the Nebraska Stem Cell Research Advisory Committee include the dean of each medical school in Nebraska accredited by the Liaison Committee on Medical Education (Creighton University School of Medicine and the University of Nebraska medical Center), or their designee. In addition, four scientists from outside Nebraska, with experience in non-embryonic stem cell research funded by the National Institutes of Health, also serve on the Committee, once they are appointed by the Nebraska Legislature.

2.2. Allowable and Unallowable Costs

Please refer to **Form 9 – Detailed Line-Item Budget for Proposed Project Period, Section 4.10.** and **Form 10 – Budget Justification, Section 4.11.** for information on allowable and unallowable costs. If an applicant is uncertain if their cost is allowable, they may submit an inquiry for clarification prior to March 27, 2026.

2.3. Reporting Requirements

First progress report, financial report, and budget narrative are due January 31, 2027; second progress report, financial report, and budget narrative are due July 31, 2027. The Division of Public Health will provide the appropriate templates for the reports.

2.4. Post-Award Impact and Long-Term Tracking

As part of the program's commitment to assessing long-term impact, awardees may be asked to provide brief updates at designated intervals (e.g. 1,5, and 10 years following the end of the award period). These updates may include information on continued research activities, subsequent funding, publications, and other outcomes related to work supported by Nebraska Stem Cell funding.

2.5. Applicable Attachments

1. Attachment 1 – End User Guidance: Shared File Link
2. Attachment 2 – Nebraska Stem Cell Research Act

3. RFA PROCEDURE

This RFA seeks Applications to complete activities allowable under the funding source identified in 1.2, above. All Applications must conform to all instructions, conditions, and requirements included in this RFA. Applicants should carefully examine this RFA, as well as the requirements on the state or federal funds involved. Applications that DHHS determines do not conform to the requirements of this RFA, or Applications from ineligible entities, may be considered non-responsive and rejected without scoring.

3.1. RFA Point of Contact ("POC")

Office of Procurement and Grants
PO Box 94926
Lincoln, NE 68508
(531) 893-0649
DHHS.Grants@nebraska.gov

From the date the RFA is issued until the Intent to Award is issued, communication from the Applicant or prospective Applicant is limited to the POC listed above (but see exceptions, below). After the Intent to Award is issued, the Applicant may communicate with individuals DHHS has designated as responsible for negotiating the Grant on behalf of DHHS. No member of the state government, employee of the state, or member of the Evaluation Committee is empowered to make binding statements regarding this RFA. The POC will issue clarifications or opinions regarding this RFA in writing. Only the POC has the authority modify the RFA, answer questions, or render opinions on behalf of DHHS. Applicants shall not have any communication with or attempt to communicate or influence any Evaluator.

The following exceptions to these restrictions are permitted:

1. Contact made pursuant to pre-existing contracts, subawards, or obligations.
2. Contact required by the schedule of events, or an event scheduled later by the RFA POC; and
3. Contact required for negotiation and execution of the final subaward.

DHHS reserves the right to reject an Applicant's application, withdraw an Intent to Award, or terminate a Grant if DHHS determines there has been a violation of these procedures.

3.2. Schedule of Events

ACTIVITY	DATE/TIME
Release RFA	March 9, 2026
Last day to submit written questions	March 27, 2026
State responds to written questions through RFA "Addendum" and/or "Amendment" to be posted to the Internet at: http://dhhs.ne.gov/Pages/Grants-and-Contract-Opportunities.aspx	April 3, 2026
Application Review Period Begins (Application due date)	April 26, 2026
Evaluation Period	April 27, 2026 - June 30, 2026
Post "Intent to Subaward" to Internet at: http://dhhs.ne.gov/Pages/Grants-and-Contract-Opportunities.aspx	No later than June 30, 2026
Budget Period Start*	July 1, 2026

**The Budget Period start may occur before a Grant is finalized, agreed to, and executed by the parties. Because this is just the period during which costs are allowable, it does not reflect that any agreement between DHHS and any successful Applicant has gone into effect or is binding in any way. No binding agreement has been made between DHHS and any Applicant until a Grant is fully executed by both parties.*

3.3. Written Questions and Answers

Questions regarding information needed for an application, as well as the meaning or interpretation of any RFA provision, must be submitted in writing to POC via email and clearly marked "RFA Number ENTER #; Questions." The POC is not obligated to respond to questions that are received late, as set forth in the Schedule of Events.

Applicants should present, as questions, any assumptions upon which the Application is or might be developed. Applications will be evaluated without consideration of any known or unknown assumptions of an Applicant. The Grant will not incorporate any known or unknown assumptions of an Applicant.

Questions must be sent via e-mail to **DHHS.Grants@nebraska.gov**. DHHS recommends that Applicants submit questions using the following format:

RFA Section Reference	RFA Page Number	Question

Written answers will be posted at the DHHS Website per the Schedule of Events. Written answers will become part of this RFA.

3.4. Submission of Applications

3.4.1. Prior to Submission:

Each proposal must be vetted and approved by a local committee appointed by the Sponsoring Institution, or its equivalent, before it is accepted by the Committee for full review. The composition of the committee is at the discretion of the institution.

Approval of the application by the Sponsoring Institution should be based upon the degree to which the proposal appears to meet the selection criteria outlined in section **3.7 Selection Criteria**.

3.4.2. Submission

DHHS is accepting either electronically submitted responses or hard copy, paper responses for this funding opportunity. Applicants must submit a complete Application, including all the parts required herein, in one of two ways:

1. Electronic Response:

   Applicants submitting electronically can upload the response via ShareFile here:

   https://nebraska.sharefile.com/r-rbfc05165ea404148ba59289296001d37

   Applicants should reference **Attachment 1** *End User Guidance: Shared File Link* for more information regarding ShareFile.

   The submission shall include the Application as a single Portable Document Format (PDF) or multiple PDFs. Failure to provide the Application in the correct format may result in DHHS being unable to read or open the Application and thus rejecting it without Evaluation.

   The applicant should clearly identify the uploaded response files. To assist in identification, please use the following naming convention:

   RFA 6380 ABC Company

   If multiple files are submitted for one funding opportunity, add number of files to file names:

   RFA 6380 ABC Company File 1 of 2

   It is the applicant's responsibility to submit the response by the date and time indicated in the Schedule of Events. Electronic responses must be received by DHHS by the date and time of the due date per the Schedule of Events. No late responses will be accepted.

2. Physical Mailing Response:

   Option 1. Submission directly to the POC via United States Postal Service mail. The Application shall be sent to the POC's address listed above in Point of Contact, Section 3.1. The Application itself shall remain sealed and shall not be opened until the beginning of the Application Review Period.

   Option 2. Hand delivered responses, or responses delivered by FedEx or UPS should be delivered to:

   ATTN: Office of Procurement and Grants
   DHHS – 3rd Floor Reception Desk
   301 Centennial Mall South
   Lincoln, NE 68509

   The Application itself shall remain sealed and shall not be opened until the beginning of the Application Review Period.

   Regardless of the submission method, Applicants must use the forms supplied by DHHS in this RFA unless specifically otherwise indicated herein. All Applications must be received by the beginning of the Application Review Period, as stated in the Schedule of Events, Section 3.2

3.5. Evaluation Committee

The research scientists on the Nebraska Stem Cell Research Advisory Committee evaluate the Applications on behalf of DHHS.

Any contact, attempted contact, or attempt to influence an evaluator that is involved with this RFA may result in the rejection of this Application and further administrative actions.

3.6. Evaluation of Applications

DHHS will evaluate all Applications for responsiveness, to determine whether the Applicant is an eligible entity; whether the Application meets the minimum requirements of this RFA; and whether the Applicant poses risk of noncompliance with state statutes, regulations, and the terms and conditions of the Grant, such that DHHS should not award funding.

All complete Applications that are responsive to the RFA will be evaluated by the research scientists on the Nebraska Stem Cell Research Advisory Committee. The research scientists reserve the right to evaluate Applicants and award funds in a manner utilizing criteria selected at the Nebraska Stem Cell Research Advisory Committee's discretion and in the best interest of meeting the objectives of the funding involved.

Applications are evaluated using the current National Institutes of Health (NIH) scoring system from 1 to 9 where the lowest scores indicate the highest level of merit (https://grants.nih.gov/grants/policy/review/rev_prep/scoring.htm). NIH expects that scores of 1 or 9 will be used less frequently than the other scores. Five (5) is for a good medium-impact application and considered an averages score. No formula is used to derive the overall impact score from the individual criterion scores, and reviewers are instructed to weigh the different criteria as they see fit in deriving their overall scores. Note that an application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high impact score. The research scientists may seek outside expertise and assistance in providing the most knowledgeable and fair evaluations of the grant proposals. Each Applicant that applies will receive strengths and weaknesses of their proposal from the research scientists.

When the evaluation process is complete, the recommendations of the Nebraska Stem Cell Research Advisory Committee will be forwarded to the Division of Public Health's Chief Medical Officer for final approval.

3.7. Selection Criteria

A outlined in the Code of Federal Regulations Title 42, Chapter I Subchapter D Part 52 h (eCFR :: 42 CFR Part 52h -- Scientific Peer Review of Research Grant Applications and Research and Development Contract Projects) and in accordance with § 52h.7, the scientific peer review group shall assess the overall impact that the project could have on the research field involved, taking into account, among other pertinent factors:

3.7.1 Significance: Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced?

3.7.2 Approach: Are the conceptual framework, design, methods, and analyses adequately developed, well integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternatives?

3.7.3 Innovation: Does the project employ novel concepts, approaches, or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?

3.7.4 Principial Investigator: Is the PI appropriately trained and well suited to carry out his work? Is the work proposal appropriate to the experience level of the PI and other researchers (if any)?

3.7.5 Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employe useful collaborative arrangements?

DHHS will award to multiple top scoring Applicants, at its sole discretion. If all Applicants meet the minimum requirements and are meritorious, DHHS may also elect to award all Applicants.

3.8. Late Applications

Applications received after the time and date of the Application opening will be considered late Applications. Late Applications will be rejected. All Applications must be electronically or physically received by the date and time of the Application Opening. The State is not responsible for Applications that are late or lost regardless of cause or fault. It is the Applicant's responsibility to ensure Applications are received timely.

3.9. Corrections

An Applicant may correct a mistake in an application prior to the time of opening by giving written notice to the POC of intent to withdraw the Application for modification, or to withdraw the Application completely. Changes in an Application after the Evaluation Period has begun are acceptable only if the change is made to correct a minor error. Whether an error is minor shall be determined by DHHS.

3.10. Grievance and Protest Procedures

All grievances must follow the DHHS Subaward Grievance/Protests Procedures, available on the DHHS website. Grievances must be filed timely.

3.11. DHHS Reservations of Authority During Application and Evaluation Process

After Evaluation of the Applications, or at any point in the RFA process, DHHS may take one or more of the following actions:

1. Amend the RFA.
2. Extend the time of or establish a new Application opening time (i.e., allowing additional time to submit Applications).
3. Waive deviations or errors in the RFA process and in Applications that are not material, do not compromise the RFA process or an application, and do not improve an Applicant's position.
4. Accept or reject a portion of or all of an application.
5. Accept or reject all Applications.
6. Withdraw the RFA.
7. Elect to reissue the RFA.

DHHS reserves the right to adjust the Applicant's budget with successful Applicants after the Intent to Subaward is issued. DHHS also reserves the right to adjust the Work Plan with Applicant to meet the requirements of the grant, Federal Funding Agency, law, or to meet DHHS programmatic needs. DHHS also reserve the right to apply additional conditions based on the successful Application and the result of a pre-award risk assessment. If a scoring method is used to rank applications to determine funding amounts, all adjustments shall have no bearing on rank.

If DHHS rejects all Applications, it may enter either reissue an RFA with the same or different specifications and terms, or it may negotiate a single or multiple Subawards with individual Applicants or non-Applicants.

4. APPLICATION INSTRUCTIONS

4.1. Application Contents

A complete, responsive Application must contain the following completed documents:

4.1.1. Form 1 – Application Cover Sheet
4.1.2. Form 2 – Face Page
4.1.3. Table of Contents
4.1.4. Form 3 – Abstract and Specific Aims of the Project
4.1.5. Form 4 – Description of Key Personnel
4.1.6. Form 5 – Biographical Sketch: Principal Investigator and Others
4.1.7. Form 6 – Previous and Current Related Projects Funded
4.1.8. Form 7 – Research Plan
4.1.9. Form 8 – References

4.1.10. Form 9 – Detailed Line-Item Budget for Proposed Project Period
4.1.11. Form 10 – Budget Justification
4.1.12. Form 11 – Attestation of Use as Match

Applications that do not contain all required sections will be rejected.

4.2. Form 2 - Face Page

Each Application must include a completed Face Page which includes the research institution, principal investigator, amount of grant request, and signature of both the Principal Investigator and authorized institutional representative.

4.3. Table of Contents

A Table of Contents is required of all Applications and must include items noted in Section 4.1.

4.4. Form 3 - Abstract and Specific Aims of the Project

List the Application's specific aims and make a clear statement of the project's relevancy to stem cell research. Describe concisely the research design and methods for achieving these goals. Avoid summaries of past accomplishments and the use of the first person. This abstract is meant to serve as a succinct and accurate description of the proposed work when separated from the application. There is a maximum of 30 lines of text. Applicant must complete an Abstract form which becomes part of the Application.

4.5. Form 4 - Description of Key Personnel

Key personnel are defined as, and should be limited to, individuals who contribute in a substantive way to the scientific development or execution of the project, whether or not salaries are requested. The PI must be an independent investigator with an appropriate faculty appointment, adequately assigned laboratory space, and the ability to apply for federal grants as a PI. If there are Co-Principal Investigators, only one may be designated as the Principal Investigator on the Application Face Page. This individual is the point of contact for the Application.

Junior applicants may apply if they provide a statement or letter from their chairperson specifically confirming their faculty level appointment, the amount of independent research space available to them and that they are considered eligible to apply for federal grants as a PI.

Consultants should be included only when their level of involvement meets the definition. Individuals providing technical services are not considered key personnel. For each individual, provide name, organization, and role on the project. Under role on the project, indicate how the individual will function regarding the proposed project, for example, principal investigator, graduate research assistance, etc. (two page maximum.

Applicant must complete a Description of Key Personnel form which becomes part of the application.

4.6. Form 5 - Biographical Sketch: Principal Investigator and Others

Applicants must complete a Biographical Sketch form for key personnel, consultants, and collaborators which becomes part of the Application. List the principal investigator first.

Research and professional experience: Concluding with present position, list, in chronological order, previous employment, experience, and honors. List, in chronological order, the titles, all authors, and complete references of recent peer reviewed publications and representative earlier publications pertinent to this application only. This section should not exceed three additional pages (applicants may use the NIH 398 form). There is a maximum of four pages for each individual, even if the NIH 398 form is used.

4.7. Form 6 - Previous and Current Related Projects Funded

Please list all active and pending extramural sources of funding, as well as previously funded projects from the past three years for the Principal Investigator and Key Personnel. For each project, list:

1. the project title.
2. budget amount and PI percent effort
3. source and period of funding
4. project abstract including Specific Aims.

Prior Nebraska Stem Cell Funding *(if applicable)*

Applicants who have previously received Nebraska Stem Cell funding must include a brief summary (up to 2 pages) describing the outcomes of the prior award. This section should address the following:

1. The long-term impact of the prior Nebraska Stem Cell funding on the applicant's research program.
2. Key scientific, translational, or clinical outcomes resulting from the award.
3. Subsequent studies, grants, or external funding that were enabled or informed by Nebraska Stem Cell supported work.
4. Publications, intellectual property, or other scholarly outputs arising from the prior award.

Applicants should also describe how the proposed project builds upon, diverges from, or is otherwise distinct from work supported during the initial funding period.

4.8. Form 7- Research Plan

The Research Plan should include sufficient information to facilitate an effective review. Be specific and informative and avoid redundancies. Reviewers often consider brevity and clarity in the presentation to be indicative of a principal investigator's focused approach to a research objective and ability to achieve the specific aims of the project.

Organize Sections A-D of the Research Plan to answer these questions: (A) What do you intend to do? (B) Why is this work important? (C) What has already been done? (D) How are you going to do the work? Do not exceed five pages, including all tables and graphs. **A five-page absolute maximum will be strictly enforced. Applications that exceed this limit, or that exceed the type size limitations, will be returned without review.** You may use any page distribution within this overall limitation adhering to the following format:

A. Specific Aims. State the broad, long-term objectives and describe concisely and realistically what the specific research described in this application is intended to accomplish and any hypotheses to be tested.

B. Background and Significance. Briefly sketch the background to the present proposal, critically evaluate existing knowledge, and specifically identify the gaps in which the project is intended to fill. State concisely the importance of the research described in this application by relating the specific aims to the broad, long-term objectives.

C. Preliminary Studies. Provide an account of the principal investigator's preliminary studies pertinent to the application and/or any other information that will help to establish the experience and competence of the investigator to pursue the proposed project.

D. Research Design and Methods. Outline the research design and the procedures to be used to accomplish the specific aims of the project. Include the means by which the data will be collected, analyzed, and interpreted. Describe any new methodology and its advantage over existing methodologies. Discuss the potential difficulties and limitations of the proposed procedures and alternative approaches to achieve the aims. Provide a tentative sequence or timetable for the investigation. Point out any procedures, situations, or materials that may be hazardous to personnel and the precautions to be exercised.

Although no specific page limitation applies to the following sections (E-G) of the application, it is important to be succinct.

E. Consultants/Collaborators. Include biographical sketch pages for each consultant and collaborator and place them with those of the other participants on the project.

F. **Contractual Arrangements**. Provide a detailed explanation of the programmatic, fiscal, and administrative arrangements made between the applicant organization and the collaborating organizations and individuals. Attach confirming letters countersigned by an authorized official of the collaborating institutions and principal investigator or copies of written agreements.

G. **Literature Cited.** Do not scatter literature citations throughout the text. List them on a separate page at the end of the Research Plan. Each literature citation must include the title of the article, the names of all authors, the name of the book or journal, volume number, page numbers, and year of publication. Make every attempt to be judicious in compiling a relevant and current list of literature citations.

Gender and Minority Inclusion: According to the NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research (2001), applications for grants that involve human subjects are required to include minorities and both genders in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder, or condition under study. Special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders, and conditions in which disproportionately affect them.

IRB (Institutional Review Boards), IACUC (Institutional Animal Care and Use Committee), and IBC (Institutional Biosafety Committee) Approval: If this proposal employs the use of human subjects or materials (IRB), use of animals (IACUC), or use of recombinant DNA (IBC), the necessary approval(s) by the appropriate IRB, IACUC, or IBC at the institutions must be obtained prior to the actual expenditure of any awarded funds. IRB, IACUC and IBC applications should be submitted through campus approval channels in a timely way to allow "just-in-time" processing and funding of possible awards. No research employing human subjects, animal subjects, or recombinant DNA may be initiated prior to full approval of related protocol applications.

Applicant must complete a Research Plan form which becomes part of the Application.

4.9. Form 8 - References

References should be single-spaced with no page limit. Applicants must complete a References form which becomes part of the Application.

4.10. Form 9 - Detailed Line-Item Budget for Proposed Project Period

Applicants must include a Detailed Line-Item Budget for the proposed project period. List only the direct costs requested in this Application. Direct costs are those that can be identified specifically within a particular cost objective.

The Line-Item Budget must be completed for funding proposed for July 1, 2026, through June 30, 2027, period.

Applications which fail to present itemized budgets, and justification will be judged incomplete and will not be considered for funding.

Personnel:

Personnel costs should include salaries and wages paid for services rendered to the research project. Personnel costs should be budgeted in relation to the amount of time and effort expected to be devoted to the project by each individual involved.

Professional salaries for the Principal Investigator and doctoral level co-investigators as well as clerical or administrative assistants are not allowed (but may be included in the matching funds section of the line-item budget). Allowable budget items include non-professional salaries (e.g., laboratory assistants, post-doctorates, and graduate assistants), equipment, travel, and other expenses such as consultant costs.

Personnel costs should be itemized by position title.

Percent of Effort on Project. Indicate the percentage of each appointment at the applicant organization to be devoted to this project.

Salary Requested. Enter the dollar amounts for each position for which funds are requested. The maximum salary that may be requested is calculated by multiplying the individual's base salary, defined above, by the percentage of effort on this project. Professional salaries for the Principal Investigator and doctoral level co-investigators as well as clerical or administrative assistance are NOT allowed. The applicant must designate the percentage of FTE for the Principal Investigator and indicate any matching funds.

Benefits:

Fringe Benefits. Fringe benefits may be requested in accordance with the existing rate established by the applicant organization. The applicant must provide information of the benefits for each position funded and itemize fringe benefits (i.e., health insurance, retirement, FICA, tuition assistance).

Operating Expenses:

Supplies. Supplies, both laboratory and office, that are expected to be consumed in the conduct of the project, should be budgeted. Itemize supplies in separate categories such as glassware, chemicals, radioisotopes, office supplies, etc.

Travel:

Travel expenses are allowable only when incurred for the purposes of collecting, receiving, or delivering samples. State the purpose of any travel, giving the number of trips involved, the destinations, and the number of individuals for whom funds are requested. Travel expenses to attend national, international, professional research, or educational conferences are not allowed. Milage shall be reimbursed at the current federal milage rate.

Other:

Equipment. Equipment means tangible, nonexpendable, personal property having a useful life of more than one year and an acquisition cost of $10,000.00 (ten thousand dollars) or more per unit. See 2 CFR § 200.313 for additional information. **Office equipment**, such as a copier or plotter, will not be allowed. However, if applicants are uncertain their equipment needs are allowable, they can submit an inquiry for clarification prior to March 27, 2026.

Consultant Costs. Whether or not costs are involved, provide the names and organizational affiliations of any consultants, including physicians in connection with patient care, who have agreed to serve in that capacity. Consultants are usually individuals organizationally separate from the Principal Investigator. Consultant fees are not allowed for full-time faculty or researchers in other departments of the same institution of the Principal Investigator. Briefly describe the services to be performed, including the number of days of consultation, the expected rate of compensation, travel, per diem, and other related costs.

Other Expenses. Other expenses include postage, data processing, and other types of operating expenses not classified elsewhere in these instructions. These costs will only be allowable to the extent that they are incurred for the direct benefit of an approved grant (e.g., postage, copy and printing costs for forms, correspondence, and reports required or generated by an approved grant). The cost of publishing the findings in a scientific journal will be allowed up to $2,500.00 (two thousand five hundred dollars). Each item in this cost category must be identified with its associated costs. In general, telephone costs are not allowable except long-distance calls required by the nature of the project. Indirect or overhead costs, such as rent and utilities, are not allowable.

Matching Funds:

Funds provided through the Stem Cell Research Program shall be used to provide a dollar-for-dollar match of funds received by institutions or researchers from sources other than funds provided by the State of Nebraska for nonembryonic stem cell research. Applicants shall provide an attestation to this effect.

4.11. Form 10 - Budget Justification

Applicants must explain the budget in detail noting how estimated expenditures support the project aims. Describe the components of each line item and how the final figure was calculated. For example, explain the specific functions of the personnel and consultants. Describe what personnel benefits are being requested through this grant. Also, justify the purchase of equipment, usual supplies, and travel. The amounts in the budget justification total must equal the amounts in the line-item budget. There is a two-page limit on the budget justification.

If an Applicant has or has prepared a cost allocation plan for this grant, it may submit it along with the Application.

Applicants must complete a Budget Justification form which becomes part of the Application.

4.12. Form 11 – Attestation of Use as Match

Per the Neb. Rev. Stat. §71-8805 (Attachment 2 – Nebraska Stem Cell Research Act), the Applicant must attest that funds received from this RFA will be used as a dollar-for-dollar match for other funds received by UNMC for nonembryonic stem cell research. Applicants must provide source funding information including assistance listing number and amount of funds received from other sources. Applicants must agree to provide verification of source funding upon request.

4.13. Application Format

Although there is no page limit for the total application, some sections have page limitations. Grant applications that exceed the specified page limits will not be reviewed. Page limitations are as follows:

Form Number	Form Name	Page Limitation
Form 1	Application Form and Cover Sheet	One (1) Page Maximum
Form 2	Face Page	One (1) Page Maximum
NA	Table of Contents	One (1) Page Maximum
Form 3	Abstract and Specific Aims of the Project	Maximum of thirty (30) lines of text
Form 4	Description of Key Personnel	Two (2) page Maximum
Form 5	Biographical Sketch	Four (4) page Maximum per researcher (may use NIH 398 Form)
Form 6	Previous and Current Related Projects Funded	No limitations
Form 7	Research Plan Description	Five (5) page Maximum
Form 8	References	Citations should be single-spaced with no page limit
Form 9	Line-Item Budget	Applicant may request a one (1) year grant for up to $110,000 (one hundred ten thousand dollars)
Form 10	Budget Justification	Two (2) Page Maximum
Form 11	Match Attestation	One (1) Page

Except for Form 2 – Face Page, all documents should be presented in Arial 12 (twelve) point font with 1 (one) inch margins.

4.14. Additional Requirements: Each sponsoring institution may submit a maximum of five (5) proposals in a given funding cycle.

- No Principal Investigator (PI) may hold more than a single grant at any given time.

- As referenced in the Research Plan, Section 4.8 D: IRB, IACUC, and IBC Approval may be required. If a proposal employs the use of human subjects or materials (IRB), use of animals (IACUC) or use of recombinant DNS (IBC), the necessary approval(s) by the appropriate IRB, IACUC, or IBC at the institutions must be obtained prior to the actual expenditure of any awarded funds. IRB, IACUC, and IBC applications should be submitted through campus approval channels in a timely manner to allow "just-in-time" processing and funding of possible award.
- No research employing human subjects, animal subjects, or recombinant DNA may be initiated prior to full approval of related protocol applications. Applicants must attach the appropriate documentation as requested on Form 2 – Face Page.

5. TERMS

5.1. Addenda

The following Addenda will be incorporated into any Grant with a selected Applicant:

- Addendum A - DHHS General Terms – State Funds Grants
- Addendum C - HIPAA Business Associate Agreement Provisions – State Funds Grants

DHHS reserves the right to amend these terms at any time during the RFA; to negotiate the terms with selected Applicants; to amend or change these terms for any subsequent Grant signed and executed by the parties; or any combination of the above. Terms required by federal, or state law will not be negotiated, and if an Applicant cannot agree to these terms, DHHS may withdraw or modify the Intent to Award and take any of the actions set forth herein.

5.2. Budget Changes

The final Grant may contain terms to allow a Grantee to modify a budget, with approval from DHHS. If funds are reassigned between line items, prior approval from DHHS is required for cumulative budget transfers for costs exceeding twenty (20) percent of the current total approved budget. Applicants should not, however, rely on this when submitting budgets.

5.3. Direct Costs

Under this Grant, DHHS shall only pay for actual and allowable costs as consistent with the requirements in 2 CFR 200 Subpart E.

To be allowable, all costs must be necessary, reasonable, and allocable and:

- Consistent with all other law, regulation, policy, or other requirements applicable to the state funds involved.

To be actual, all costs must be finalized and spent by the appropriate dates set forth in the grant agreement. Applicants should be aware that direct personnel costs must be consistent with 2 CFR § 200.430, as applicable. These costs must be backed up by sufficient documentation or must be shown to be allocable to the award via an alternative, allowable method, such as a random time study.

5.4. Indirect Costs

Indirect costs and cost allocation plans are not allowable for subawards resulting from this RFA.

5.5 Program Income

Any revenue generated by the Grant is Program Income (see definition in 2 CFR § 200.1). Program Income requires an accounting of its use and must be handled in accordance with 2 CFR § 200.307. All program income generated by the Grants awarded as a result of this RFA must be handled under the deduction method. Please see the regulations cited above for more detail.

6. GLOSSARY OF TERMS

All terms shall have the meaning as set forth in 2 CFR §§ 200 et seq. unless otherwise specifically set forth herein.

Agent/Representative: A person authorized to act on behalf of another.

Amend: To alter or change by adding, subtracting, or substituting.

Amendment: A written correction or alteration to a document.

Applicant: Non-Federal Entity that has applied for funding under this RFA.

Application: The written proposal submitted by the Applicant applying for funding under this RFA, which is composed of Forms 1 through 5.

Application Due Date: The date the RFA must be submitted to DHHS, and if not submitted by that time, rejected.

Budget Period: The time interval from the start date of a funded portion of an award to the end date of that funded portion during which recipients are authorized to expend the funds awarded, including any funds carried forward or other revisions pursuant to § 200.308.

Co-Principal Investigator (Co-PI): An investigator who shares scientific and administrative leadership responsibilities for a project with the PI.

DHHS Website: www.dhhs.ne.gov.

Equipment: tangible personal property (including information technology systems) having a useful life of more than one year and a per-unit acquisition cost which equals or exceeds the lesser of the capitalization levels established by the non-Federal entity for financial statement purposes, or $5,000.00 (five thousand dollars).

Evaluation: The process of examining an Applicant after opening to determine the Applicant's responsibility, responsiveness to requirements, and to ascertain other characteristics of the Application that relate to determination of the successful award.

Evaluation Committee: Committee(s) appointed by DHHS that advises and assists DHHS in the evaluation of Applications.

Evaluator: An individual on the Evaluation Committee who advises and assists in the evaluation of Applications.

Grant: The Agreement executed, pursuant to the terms of the RFA, between DHHS and the Applicant.

Grantee: The entity that has executed a Grant with DHHS.

Human Embryo: The developing human organism from the time of fertilization until the end of the eighth week of gestation and includes an embryo or developing human organism created by somatic cell nuclear transfer.

Institutional Base Salary: Institutional base salary is defined as the annual compensation that the applicant organization pays for the individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of duties to the applicant organization. Base salary may not be increased as a result of replacing institutional salary funds with grant funds.

Indirect costs: are costs incurred for a common or joint purpose benefitting more than one cost objective, and not readily assignable to the cost objectives specifically benefitted, without effort disproportionate to the results achieved as defined in 2 CFR § 200.1.

Institutional Animal Care and Use Committee (IACUC): Responsible for oversight of the animal care and use program and its components as described in the Public Health Services (PHS) Policy on Humane Care and Use of Laboratory Animals (Policy) and the Guide for the Care and Use of Laboratory Animals (Guide). Its oversite functions include an ongoing assessment of animal care and use.

Institutional Review Boards (IRB): an independent review body comprised of medical, scientific, and non-scientific members established and designated by an entity (often a hospital, research center, or university) to ensure the protection of the rights, safety, and well-being of human subjects recruited to participate in biomedical or behavioral research according to the requirements outlined in Title 38 part 16 of the U.S. Code of Federal Regulations.

Intent to Award: A document noting the results of the RFA evaluation process and identified any identified Applicant(s) with whom DHHS intends to award federal funds, but not a binding agreement with any promise to award.

Just-in-Time Procedures: certain elements of an application may be submitted later in the application process, after review when the application is under consideration for funding. The standard application elements include other support information (both active and pending) for senior/key personnel; certification of IRB approval of the project's proposed use of human subjects; verification of IACUC approval of the project's proposed use of live vertebrate animals; and evidence of compliance with the education in the protection of human resource participant requirements.

Mandatory/Must: Required, compulsory, or obligatory.

May: Discretionary, permitted; used to express possibility.

Must: See Mandatory/Must and Shall/Will/Must.

National Institute of Environmental Health Sciences (NIEHS) Institutional Biosafety Committee (IBC): is chartered to approve permits for the use of recombinant DNA, human materials, and potentially hazardous biological materials. The IBC will promote training in the use of these materials and provide Institutional oversite in their use.

National Institutes of Health (NIH): A part of the U.S. Department of Health and Human Services and is the nation's medical research agency.

Nebraska Stem Cell Research Advisory Committee ("The Committee"): Committee responsible for developing a grant process and making grants to Nebraska institutions or researchers to conduct stem cell research that does not use human embryonic stem cells.

Non-Responsive: When an application does not meet the minimum requirements of this RFA.

Oocyte: A female germ cell in the process of development.

Point of Contact ("POC"): The person designated to receive communications and to communicate.

Principal Investigator (PI): the person or persons in charge of a clinical trial or scientific research grant. The principal investigator prepares and carries out the clinical trial protocol (plan for the study) or research paid for by the grant. The principal investigator also analyses the data and reports the results of the trial or grant research.

Recombinant DNA: a molecule of DNA that has been modified to include genes from multiple sources.

Request for Applications ("RFA"): Written solicitation of competitive applications for federal grant funding.

Shall/Will/Must: An order/command; mandatory.

Should: Expected; suggested, but not necessarily mandatory.

Somatic Cell: Any cell of a living organism other than the reproductive cells.

Somatic Cell Nuclear Transfer: A technique in which the nucleus of an oocyte is replaced with the nucleus of a somatic cell.

Sponsoring Institution: an organization or entity that assumes the ultimate financial and academic responsibility for a program of graduate medical education (GME).

Stem Cell Research Act (Neb. Rev. Stat. § 71-8801): Established the Stem Cell Research Advisory Committee which is responsible for developing a grant process and making grants to Nebraska institutions or researchers to conduct stem cell research that does not use human embryonic stem cells.

Uniform Grants Guidance ("UGG"): The regulations codified at 2 CFR §§ 200 et seq., which provide the general administrative requirements for grant funding flowing down from the federal government. See also HHS Grants Guidance.

Will: See Shall/Will/Must.

FORM 1 – APPLICATION COVER SHEET

Instructions: This form must be signed and returned, along with the application materials, before the Application Due Date, to the POC or designated email address, as applicable.

RFA #	RELEASE DATE
R-6251	March 9, 2026
APPLICATION DUE DATE	**POINT OF CONTACT**
April 26, 2026	Office of Procurement and Grants

CERTIFICATION AND GUARANTEE OF COMPLIANCE

By signing this Application Cover Sheet, the Applicant guarantees compliance with the provisions stated in this Request for Application and certifies that all information contained in this Application is accurate. This Application is submitted pursuant to the terms of the RFA, and if the Applicant is awarded funding, it will be incorporated into the Subaward between the parties. I understand that if anything in this Application conflicts with the RFA or with the subsequent Subaward, the Subaward and RFA shall govern as set forth in the Subaward.

Organization Name: _____

Principal Investigator Name: _____

Project Title: _____

Organization UEI Number: _____ Organization EIN Number: _____

Complete Address: _____

_____

Congressional District: _____

Telephone Number: _____ E-Mail Address: _____

_____ I certify that this organization is an "eligible organization" as defined by this RFA.

_____ I certify that this organization is NOT presently debarred or suspended.

Signature: _____

Name and Title of Signatory: _____

** Applicants must ensure that the organization name entered on the application matches the legal name associated with the organization's UEI registration in **SAM.gov**.*

FORM 2 – FACE PAGE

Nebraska Department of Health and Human Services **Stem Cell Research Grant Application** Follow Instructions Carefully	Leave Blank for Department of Health and Human Services
1. Title of Project (**Do not exceed 50 characters**, including spaces and punctuation.)	
2. Principal Investigator Name (Last, first, middle)	2a. Degree(s)
2b. Position Title	2c. Mailing Address of PI (Organization, street, city, state, zip) Organization: Street Address: City, State, Zip:
2d. Department, Service, Laboratory or Equivalent	
2e. Major Subdivision	
2f. PI Contact Numbers (Area code, number, and extension) Telephone: Fax: E-mail Address:	2g. ☐ New Application ☐ Revised Application (This application replaces a prior Unfunded version of the new competing application # _____).
3. Human Subjects If yes, IRB approval or exemption date (attach copy) ☐ No ☐ Yes _____	4. Vertebrate Animals (IACUC) If Yes, Review Board approval date (attach copy) ☐ No ☐ Yes _____
5. Recombinant DNA (IBC) If Yes, Review Board approval date (attach copy) ☐ No ☐ Yes _____	6. Proposed Project Period: July 1, 2026 – June 30, 2027 Total Direct Costs Requested:
7. Administrative official to be notified if award is made. Name: Title: Address: Telephone: Fax: E-mail Address:	8. Name of Official Signing for Applicant Organization Name: Title: Address: Telephone: Fax: E-mail Address:
9. Principal Investigator/Program Director Assurance: I certify that the statements herein are true, complete, and accurate to the best of my knowledge. I agree to accept responsibility for the scientific conduct of the project and to provide the required progress reports, if a grant is awarded as a result of this application.	Signature of person named in 2. (In ink. "Per" signature not acceptable.) Date _____
10. Application Organization, Certification and Acceptance: I certify that the above statements herein are true, complete, and accurate to the best of my knowledge and accept the obligation to comply with Department regulations and conditions if a grant is awarded as a result of this application.	Signature of person named in 8. (In ink. "Per" signature not acceptable.) Date _____

FORM 3- ABSTRACT AND SPECIFIC AIMS OF THE PROJECT

Principal Investigator/Program Director (Last, first, middle):

Applicant Organization:

Abstract Title:

Abstract

List the application's specific aims and make a clear statement of the project's relevancy to stem cell research. Describe concisely the research design and methods for achieving these goals. Avoid summaries of past accomplishments and the use of the first person. This abstract is meant to serve as a succinct and accurate description of the proposed work when separated from the application. There is a maximum of 30 lines of text.

FORM 4 – DESCRIPTION OF KEY PERSONNEL

Principal Investigator/Program Director (Last, first, middle):

Applicant Organization:

Abstract Title:

Key Personnel

Key personnel are defined as, and should be limited to, individuals who contribute in a substantive way to the scientific development or execution of the project, whether or not salaries are requested. The PI must be an independent investigator with an appropriate faculty appointment, adequately assigned laboratory space, and the ability to apply for federal grants as a PI.

Junior applicants may apply if they provide a statement or letter from their chairperson specifically confirming their faculty level appointment, the amount of independent research space available to them and that they are considered eligible to apply for federal grants as a PI.

Consultants should be included only when their level of involvement meets the definition. Individuals providing technical services are not considered key personnel. For each individual, provide their name, organization, and role on the project. Under role on the project, indicate how the individual will function with regard to the proposed project, for example, principal investigator, graduate research assistance, etc. (two page maximum).

Use another page as needed to provide the required information in the format shown below.

Name	Organization	Role on Project

FORM 5 – BIOGRAPHICAL SKETCH: PRINCIPAL INVESTIGATOR AND OTHERS

Principal Investigator/Program Director (Last, first, middle):

Applicant Organization:

Abstract Title:

<table>
<tr><td colspan="4">Biographical Sketch

Give the following information for the key personnel and consultants and collaborators. Begin with the principal Investigator/program director. Photocopy this page for each person.</td></tr>
<tr><td colspan="2">Name</td><td colspan="2">Position Title</td></tr>
<tr><td colspan="4">Education (begin with baccalaureate or other initial professional education, such as nursing, and include post-doctoral training)</td></tr>
<tr><td>Institution and Location</td><td>Degree</td><td>Year Conferred</td><td>Field of Study</td></tr>
<tr><td></td><td></td><td></td><td></td></tr>
</table>

Research and professional experience: Concluding with present position, list, in chronological order, previous employment, experience, and honors. List, in chronological order, the titles, all authors, and complete references of recent peer reviewed publications and representative earlier publications pertinent to this application only. This section should not exceed three additional pages (applicants may use the NIH 398 form). There is a maximum of four pages for each individual, even if the NIH 398 form is used.

FORM 6 – PREVIOUS AND CURRENT RELATED PROJECTS FUNDED

Principal Investigator/Program Director (Last, first, middle):

Applicant Organization:

Abstract Title:

Previous and Current Related Projects

Please list all active and pending extramural sources of funding, as well as previously funded projects from the past three years for the Principal Investigator and all Key Personnel. For each project, list:

(1) the project title

(2) budget amount and PI percent effort

(3) source and period of funding

(4) project abstract including Specific Aims.

Prior NE Stem Cell Funding *(if applicable)*

Applicants who have previously received NE Stem Cell funding must include a brief summary (up to 2 pages) describing the outcomes of the prior award. This section should address:

- The long-term impact of the prior NE Stem Cell funding on the applicant's research program.
- Key scientific, translational, or clinical outcomes resulting from the award.
- Subsequent studies, grants, or external funding that were enabled or informed by Nebraska Stem Cell supported work.
- Publications, intellectual property, or other scholarly outputs arising from the prior award.

Applicants should also describe how the proposed project builds upon, diverges from, or is otherwise distinct from work supported during the initial funding period.

FORM 7 – RESEARCH PLAN

Principal Investigator/Program Director (Last, first, middle):
Applicant Organization:
Abstract Title:

Research Plan

Organize Sections A-D of the Research Plan to answer these questions:

1. What do you intend to do?
2. Why is this work important?
3. What has already been done?
4. How are you going to do the work?

Do not exceed five pages, including all tables and graphs. **A five-page absolute maximum will be strictly enforced. Applications that exceed this limit, or that exceed the type size limitations, will be returned without review.** You may use any page distribution within this overall limitation adhering to the following format:

A. Specific Aims. State the broad, long-term objectives and describe concisely and realistically what the specific research described in this application is intended to accomplish and any hypotheses to be tested.

B. Background and Significance. Briefly sketch the background to the present proposal, critically evaluate existing knowledge, and specifically identify the gaps in which the project is intended to fill. State concisely the importance of the research described in this application by relating the specific aims to the broad, long-term objectives.

C. Preliminary Studies. Provide an account of the principal investigator's preliminary studies pertinent to the application and/or any other information that will help to establish the experience and competence of the investigator to pursue the proposed project.

D. Research Design and Methods. Outline the research design and the procedures to be used to accomplish the specific aims of the project. Include the means by which the data will be collected, analyzed, and interpreted. Describe any new methodology and its advantage over existing methodologies. Discuss the potential difficulties and limitations of the proposed procedures and alternative approaches to achieve the aims. Provide a tentative sequence or timetable for the investigation. Point out any procedures, situations, or materials that may be hazardous to personnel and the precautions to be exercised.

Although no specific page limitation applies to the following sections (E-G) of the application, it is important to be succinct.

E. Consultants/Collaborators. Include biographical sketch pages for each consultant and collaborator and place them with those of the other participants on the project.

F. Contractual Arrangements. Provide a detailed explanation of the programmatic, fiscal, and administrative arrangements made between the applicant organization and the collaborating organizations and individuals. Attach confirming letters countersigned by an authorized official of the collaborating institutions and principal investigator or copies of written agreements.

G. Literature Cited. Do not scatter literature citations throughout the text. List them on a separate page at the end of the Research Plan. Each literature citation must include the title of the article, the names of all authors, the name of the book or journal, volume number, page numbers, and year of publication. Make every attempt to be judicious in compiling a relevant and current list of literature citations.

FORM 8 - REFERENCES

Principal Investigator/Program Director (Last, first, middle):

Applicant Organization:

Abstract Title:

References (single-space with no page limit)

FORM 9 – DETAILED LINE-ITEM BUDGT FOR PROPOSED PROJECT PERIOD

Principal Investigator/Program Director (Last, first, middle):

Applicant Organization:

Abstract Title:

Line-Item Budget

Line Item	Grant Funds Requested
Personnel	
PI ___% FTE	
Laboratory Asst __% FTE	
Others/Specify	
SUBTOTAL	
Benefits	
SUBTOTAL	
Operating Expenses	
Supplies	
Other (specify):	
SUBTOTAL	
Travel	
SUBTOTAL	
Other (specify)	
Equipment	
Consultants	
SUBTOTAL	
TOTAL	

FORM 10 – BUDGET JUSTIFICATION

Principal Investigator/Program Director (Last, first, middle):

Applicant Organization:

Abstract Title:

Budget Justification (two-page limit)

Applicants must explain the budget in detail noting how estimated expenditures support the project aims. Describe the components of each line item and how the final figure was calculated. For example, explain the specific functions of the personnel and consultants. Describe what personnel benefits are being requested through this grant. Also, justify the purchase of major equipment, usual supplies, and travel. The amounts in the budget justification total must equal the amounts in the line-item budget. There is a two-page limit on the budget justification.

If an Applicant has or has prepared a cost allocation plan for this grant, it may submit it along with the Application.

Identify how Grant Funds will be used to match funds received by institutions or researchers from sources other than funds provided by the State of Nebraska for nonembryonic stem cell research.

FORM 11 – BUDGET JUSTIFICATION

Nebraska Stem Cell Research Project

Attestation Letter for Match Requirements

TO: Nebraska Department of Health & Human Services, Division of Public Health

RE: Nebraska Stem Cell Grant Requirements

Per the Neb. Rev. Stat. §71-8805, Choose an item attests it is using the Stem Cell Research grant for a dollar-for-dollar match for other funds received by Choose an item for nonembryonic stem cell research for the following grant:

Grant #Click or tap here to enter text.: Stem Cell 2026 # Click or tap here to enter text.

Total Grant Amount: $Click or tap here to enter text.

Principal Investigator:Click or tap here to enter text.

Project Title:Click or tap here to enter text.

Amount of funds received from other sources: Click or tap here to enter text.

Sources of other funds including the Assistance Listing number and funder:

Click or tap here to enter text.

Should DHHS require verification of the above-mentioned funds, please contact Click or tap here to enter text. at your convenience.

Sincerely,

_____ _____

Signature of Authorized Officer Date

Printed Name:Click or tap here to enter text.

Title: Click or tap here to enter text.

Attachment 1 – End User Guidance: Shared File Link

STEP 1:

Click the URL link to the ShareFile folder.

Enter the required information and Click “Continue” button.

ShareFile works with Firefox, Internet Explorer, and Chrome web browsers. **ShareFile does not work with Microsoft Edge.**



STEP 2:

Upload or drag files to upload them.

Applicants should clearly identify the uploaded response files. To assist in identification please use the following naming convention: **RFA XXXX ABC Company**

If multiple files are submitted for one funding opportunity, add number of files to file names: **RFA XXXX ABC Company File 1 of 2**



STEP 3:
Verify and submit loaded documents.

Click the “Upload” button to submit.



An uploaded document will show up as “Uploaded” in green highlight on the screen.



STEP 4:
Verify the file has Uploaded successfully.

The system will generate a confirmation of the upload to be sent to the email address that was entered in STEP 1.

If you do not receive this confirmation, your file may not have been received.



Assistance with technical issues can be found at https://www.sharefile.com/support